-
Kroenke to buy baseball's Los Angeles Angels: statement
-
Cobolli claws out five-set victory at rain-hit US Open
-
US defends Trump's Venezuela oil deal
-
Ndiaye seizes 'chance of a lifetime' in Man City move
-
OpenAI to launch new model with 'stronger safeguards' after hack
-
Global bond sell-off, surging oil prices send markets into the red
-
Fans mourn 'bittersweet' final Ariana Grande gig in London
-
Zuckerberg, Musk make plea at G20 for more AI data centers
-
Norway's King Haakon VIII swears allegiance to constitution
-
'Discomfort' at G20 finance talks as US hosts Russian minister
-
Syria site infrastructure 'consistent with nuclear reactor': IAEA
-
Man City set to sign Fernandez for record fee, Ndiaye on deadline day
-
Juventus sign Woltemade, Sarr on loan from Premier League
-
Back-to-school in Cuba a grim day with shortages of everything
-
US strikes Iran in latest tit-for-tat attacks
-
Canadian minister says Russia's G20 presence sparked 'discomfort'
-
China's Xi arrives in Egypt as US sanctions threat looms over Iran links
-
IMF reaches agreement with Senegal on new $2.2 bn loan programme
-
Car bomb at Colombian police station kills one, injures 11
-
Germany blames Russia for airport drone incident, hits back with sanctions
-
Rain delays start of play on US Open
-
Iran president urges return to truce, hails Russian support
-
Man City agree blockbuster deal to sign Chelsea star Fernandez: reports
-
Aster and World Liberty Financial Launch USD1 RWA Boost: Phase 1, Offering 125M $WLFI + 6.25M USD1 in Rewards
-
Alkemya Metacore Secures $50M via Tokenised Equity to Scale Nickel Energy and Security Tech
-
Tronchon sprints to Vuelta stage 10 win, Mas keeps red jersey
-
Man City chase Fernandez, Arsenal sell Jesus on deadline day
-
Germany defender Rudiger announces international retirement
-
EU says Russian 'hybrid attacks' won't halt aid to Ukraine
-
Musk defends AI data centers, slams EU rules at G20
-
Explosives used in sabotage attack on German power lines
-
Activists blame Kenya for Ugandan opposition figure's plight
-
Nepali families hold symbolic funerals for missing after floods
-
Iran president offers US olive branch, hails Russian support
-
Newcastle sign Lille forward Fernandez-Pardo
-
TrustFinance Community Choice Awards 2026 Opens Global Voting
-
Even at Elysee, phones are handed in, Macron tells French pupils
-
Nepal disaster a climate 'warning signal': foreign minister
-
Chelsea agree to sign Atalanta's Ahanor, with Palace loan for this season
-
France winger Diaby returns to Leverkusen until 2031
-
Chelsea sign Atalanta's Ahanor and loan him to Palace
-
Barcelona confirm Jesus arrival from Arsenal
-
UK chalks up hottest summer on record for second year running
-
EU official says it's not time to 'normalize' Russia at G20 finance talks
-
China's Xi visits Egypt as US sanctions threat looms over Iran links
-
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®
-
RISE Robotics Awarded $100,000 MassVentures Grant to Accelerate Commercialization of Beltdraulic Technology
-
TrendEadvisor Launches Global Multi-Asset Platform Combining Online Investing with Social Trading
-
Global bond sell-off deepens on inflation concerns
-
India's top court drops criminal cases against protesters
Cognixion and Pupil Labs Announce Strategic Partnership to Combine Eye-Tracking with Axon-R Neural Interface
Integration of Eye-Tracking and AI-Powered EEG BCI Technologies Opens New Frontiers for Clinical Researchers
SANTA BARBARA, CA AND BERLIN, GERMANY / ACCESS Newswire / June 4, 2025 / Cognixion, a leading developer of noninvasive Brain-Computer Interface (BCI), Artificial Intelligence (AI) and Augmented Reality (AR) technology, and Pupil Labs GmbH, a leader in eye-tracking solutions, today announced a strategic partnership to integrate cutting-edge technologies to deliver an interface that measures both visual attention and neural signals. Pupil Labs' sophisticated eye-tracking software will connect with Cognixion's Axon-R SDK, allowing for seamless data collection and analysis across platforms.
High-precision eye tracking and advanced BCI electroencephalogram (EEG) capabilities will give clinical researchers powerful new tools for neuroscience, human-computer interaction, and assistive technology research. The combined technology will provide a higher level of data confidence, and a platform that can adapt to the unique needs of patients where disease progression may impact eye gaze ability, such as amyotrophic lateral sclerosis (ALS).
The partnership addresses a significant need in the research community for unified tools that can simultaneously track visual attention and neural activity with research-grade precision.
"By combining Cognixion's neural interface expertise with Pupil Labs' industry-leading eye tracking technology, we're filling a critical role in sensor architecture that isn't available with any current brain-computer interface technologies," said Andreas Forsland, CEO of Cognixion. "This partnership enables a new generation of studies that can correlate visual attention with neural activity in real-time, potentially transforming our understanding of human cognition and interaction."
The integrated solution will allow researchers to:
Rapidly prototype and deploy studies that simultaneously measure eye movements and brain activity
Leverage research-grade sensors for both modalities without complex technical integration
Access synchronized data streams through a unified developer interface
Develop applications that respond to both visual attention and neural signals
"We've seen growing demand for combined eye-tracking and EEG solutions from our research partners," said Moritz Kassner, CEO of Pupil Labs. "This collaboration with Cognixion addresses that need with a seamless integration that maintains the fidelity researchers expect from both technologies while dramatically reducing technical barriers."
The integration is expected to be particularly valuable for clinical researchers studying attention, cognitive load, human-computer interaction, and assistive technologies for individuals with motor impairments.
Technical teams from both companies have begun the integration process, with initial releases expected within six months. The companies will also collaborate on joint marketing efforts and educational resources for the research community.
For more information, please visit www.cognixion.com and www.pupil-labs.com.
About Cognixion
Cognixion is a leader in brain-computer, augmented reality, artificial intelligence and natural user interface technology. The company is dedicated to improving the lives of individuals with severe motor impairments by providing cutting-edge patented technology that allows them to independently communicate and restore physical interactions with the world around them. The Cognixion ONE™ device is the company's flagship product, and it has already received significant recognition for its design and potential to transform the lives of individuals with severe motor impairments. Cognixion has received FDA Breakthrough Device Designation for its derivative version, called Cognixion ONE Axon. The work described in this study is built upon the Cognixion ONE Axon-R, which is a version of the Axon made specifically for research purposes, and is not currently cleared by the FDA as a medical device.
About Pupil Labs
Pupil Labs is a Berlin-based company that has been pioneering wearable eye-tracking technology since 2014. At the core of their platform is NeonNet, a state-of-the-art deep learning pipeline that delivers robust, calibration-free performance. NeonNet delivers rich data - gaze, pupil diameter, blinks, and more - with research-grade precision and reliability, setting a new benchmark for real-world eye tracking. Today, Pupil Labs supports a global community of over 10,000 professional users, with nearly 1,000 scientific publications produced using their tools.
Media Contacts:
Cognixion Corp.
Escalate PR for Cognixion
[email protected]
Pupil Labs GmbH
Marc Pieper | Product Lead & Partner
[email protected]
SOURCE: Cognixion
View the original press release on ACCESS Newswire
E.Flores--AT